Search Results - "Fanale, M. A."

A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome by Vadhan-Raj, S., Fayad, L.E., Fanale, M.A., Pro, B., Rodriguez, A., Hagemeister, F.B., Bueso-Ramos, C.E., Zhou, X., McLaughlin, P.W., Fowler, N., Shah, J., Orlowski, R.Z., Samaniego, F., Wang, M., Cortes, J.E., Younes, A., Kwak, L.W., Sarlis, N.J., Romaguera, J.E.

“…Tumor lysis syndrome (TLS) is a life-threatening disorder characterized by hyperuricemia and metabolic derangements. The efficacy of rasburicase, administered…”
Get full text

Efficacy and safety of antiretrovirals in HIV-infected patients with cancer by Torres, H.A., Rallapalli, V., Saxena, A., Granwehr, B.P., Viola, G.M., Ariza-Heredia, E., Adachi, J.A., Chemaly, R.F., Marfatia, R., Jiang, Y., Mahale, P., Kyvernitakis, A., Fanale, M.A., Mulanovich, V.

“…At 30 years into the HIV infection epidemic, the optimal antiretroviral (ARV) regimen for infected patients with cancer remains unknown. We therefore sought to…”
Get full text

Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphoma by Gopal, A.K., Fanale, M.A., Moskowitz, C.H., Shustov, A.R., Mitra, S., Ye, W., Younes, A., Moskowitz, A.J.

“…The phosphatidylinositol-3-kinase delta (PI3Kδ) inhibitor idelalisib has been shown to block downstream intracellular signaling, reduce the production of…”
Get full text

Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes by Cheah, C.Y., Chihara, D., Horowitz, S., Sevin, A., Oki, Y., Zhou, S., Fowler, N.H., Romaguera, J.E., Turturro, F., Hagemeister, F.B., Fayad, L.E., Wang, M., Neelapu, S.S., Nastoupil, L.J., Westin, J.R., Rodriguez, M.A., Samaniego, F., Anderlini, P., Nieto, Y., Fanale, M.A.

“…Brentuximab vedotin (BV) is a key therapeutic agent for patients with relapsed/refractory classical Hodgkin lymphoma (cHL). The outcomes of patients…”
Get full text

Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era by Cheah, C.Y., Chihara, D., Ahmed, M., Davis, R.E., Nastoupil, L.J., Phansalkar, K., Hagemeister, F.B., Fayad, L.E., Westin, J.R., Oki, Y., Fanale, M.A., Romaguera, J.E., Wang, M.L., Lee, H., Turturro, F., Samaniego, F., Rodriguez, M.A., Neelapu, S.S., Fowler, N.H.

“…The optimal initial therapy of follicular lymphoma (FL) remains unclear. The aims of this study were to compare primary treatment strategies and assess the…”
Get full text

BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY IN ADOLESCENTS AND YOUNG ADULTS (AYAS) WITH STAGE III OR IV HODGKIN LYMPHOMA: A SUBGROUP ANALYSIS FROM THE PHASE 3 ECHELON‐1 STUDY by Crosswell, H. E, LaCasce, A. S., Bartlett, N. L, Straus, D. J, Savage, K. J, Zinzani, P. L, Collins, G. P, Fanale, M. A, Fenton, K, Dong, C, Miao, H. H, Grigg, A. P

Get full text

Induction of apoptosis in human lung cancer cells following treatment with amifostine and an adenoviral vector containing wild-type p53 by Pataer, A, Fanale, M A, Roth, J A, Swisher, S G, Hunt, K K

“…Adenoviral delivery of the p53 gene is a potential therapeutic approach for the treatment of lung cancer. Furthermore, amifostine is a cytoprotective agent and…”
Get full text

Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (cHL): randomized phase 3 KEYNOTE-204 study by Fanale, M.A., Kline, J., Chen, R., Ribrag, V., Salles, G., Matsumura, I., Zhu, Y., Ricart, A.D., Balakumaran, A., Zinzani, P.L.

Get full text

Hodgkin lymphoma and pregnancy: Outcomes based on modern chemotherapy and radiotherapy by Ballas, L. K., Fanale, M. A., Younes, A., Milbourne, A., Shirvani, S., Shihadeh, F. D., Dabaja, B. S.

“…Abstract only…”
Get full text

Outcomes of HIV-positive lymphoma patients treated in the highly active antiretroviral therapy (HAART) era by Fanale, M. A., Vigil, K., Lai, C., Feng, L., Dong, W., Younes, A., Romaguera, J. E., Fayad, L., Hagemeister, F. B., Mulanovich, V.

“…Abstract only…”
Get full text

Durable remissions with brentuximab vedotin (SGN-35): Updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL) by Pro, B., Advani, R., Brice, P., Bartlett, N., Rosenblatt, J. D., Illidge, T., Matous, J., Ramchandren, R., Fanale, M. A., Connors, J. M., Yang, Y., Sievers, E. L., Kennedy, D. A., Shustov, A. R.

“…Abstract only…”
Get full text

Phase II study of RCHOP with pegylated liposomal doxorubicin (DRCOP) for patients older than age 60 with untreated diffuse large B-cell lymphoma (DLBCL) by Rodriguez, M. A., Durand, J., Astrow, A. B., Bury, M. J., Fanale, M. A., Hagemeister, F. B., Huang, X., McLaughlin, P., Neelapu, S. S., Pro, B., Kwak, L. W., Fayad, L., Romaguera, J. E., Younes, A., Fisch, M.

“…Abstract only…”
Get full text

High response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin lymphoma, including those meeting GELF criteria by Samaniego, F., Hagemeister, F., Mclaughlin, P., Kwak, L. W., Romaguera, J., Fanale, M. A., Neelapu, S. S., Fayad, L., Orlowski, R. Z., Wang, M., Lacerte, L., Fowler, N. H.

“…Abstract only…”
Get full text

Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma by Fowler, N. H., McLaughlin, P., Hagemeister, F. B., Kwak, L. W., Fanale, M. A., Neelapu, S. S., Fayad, L., Orlowski, R. Z., Wang, M., Samaniego, F.

“…Abstract only…”
Get full text

Investigation of whether expression of bcl-2 influences the apoptotic response of doxorubicin-resistant breast cancer cells to a novel anthracycline by Fanale, M. A., Liu, Y., McKenzie, T. S., Fokt, I., Priebe, W., Hunt, K. K.

“…Abstract only…”
Get full text

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial by Fowler, Nathan H, Dr, Davis, R Eric, MD, Rawal, Seema, PhD, Nastoupil, Loretta, MD, Hagemeister, Fredrick B, Prof, McLaughlin, Peter, Prof, Kwak, Larry W, Prof, Romaguera, Jorge E, Prof, Fanale, Michelle A, MD, Fayad, Luis E, MD, Westin, Jason R, MD, Shah, Jatin, MD, Orlowski, Robert Z, Prof, Wang, Michael, Prof, Turturro, Francesco, Prof, Oki, Yasuhiro, MD, Claret, Linda C, RN, Feng, Lei, MS, Baladandayuthapani, Veerabhadran, PhD, Muzzafar, Tariq, MD, Tsai, Kenneth Y, MD, Samaniego, Felipe, MD, Neelapu, Sattva S, MD

“…Summary Background Standard treatments for indolent non-Hodgkin lymphomas are often toxic, and most patients ultimately relapse. Lenalidomide, an…”
Get full text

Utility of hTERT-driven overexpression of E2F-1 to induce selective apoptosis of human breast cancer cells by Fanale, M. A., Liu, Y., Vorburger, S., McKenzie, T., Swisher, S., Theriault, R., Hunt, K.

“…Abstract only…”
Get full text

Utility of hTERT-driven overexpression of E2F-1 to induce selective apoptosis of human breast cancer cells by Fanale, M. A., Liu, Y., Vorburger, S., McKenzie, T., Swisher, S., Theriault, R., Hunt, K.

“…Abstract only…”
Get full text

INTERIM DATA FROM THE FIRST CLINICAL STUDY OF ADCT‐301, A NOVEL PYRROLOBENZODIAZAPINE‐BASED ANTIBODY DRUG CONJUGATE, IN RELAPSED/REFRACTORY HODGKIN/NON‐HODGKIN LYMPHOMA by Horwitz, S.M., Fanale, M.A., Spira, A.I., Havenith, K., He, S., Feingold, J.M., Hamadani, M.

Get full text

Predictors of Radiation Pneumonitis in Patients Receiving Intensity Modulated Radiation Therapy for Hodgkin and Non-Hodgkin Lymphoma by Pinnix, Chelsea C., MD, PhD, Smith, Grace L., MD, PhD, Milgrom, Sarah, MD, Osborne, Eleanor M., MD, Reddy, Jay P., MD, PhD, Akhtari, Mani, MD, Reed, Valerie, MD, Arzu, Isidora, MD, Allen, Pamela K., PhD, Wogan, Christine F., MS, Fanale, Michele A., MD, Oki, Yasuhiro, MD, Turturro, Francesco, MD, Romaguera, Jorge, MD, Fayad, Luis, MD, Fowler, Nathan, MD, Westin, Jason, MD, Nastoupil, Loretta, MD, Hagemeister, Fredrick B., MD, Rodriguez, M. Alma, MD, Ahmed, Sairah, MD, Nieto, Yago, MD, PhD, Dabaja, Bouthaina, MD

“…Purpose Few studies to date have evaluated factors associated with the development of radiation pneumonitis (RP) in patients with Hodgkin lymphoma (HL) and…”
Get full text